Literature DB >> 22263067

NSCLC - immunogenic after all?

Karl-Josef Kallen1, Ulrike Gnad-Vogt.   

Abstract

Entities:  

Year:  2011        PMID： 22263067      PMCID： PMC3256506          DOI： 10.3978/j.issn.2072-1439.2011.02.01

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

Review 1.  Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Authors:  Axel Hoos; Ramy Ibrahim; Alan Korman; Kald Abdallah; David Berman; Vafa Shahabi; Kevin Chin; Renzo Canetta; Rachel Humphrey
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

Review 2.  The significant role of mast cells in cancer.

Authors:  Khashayarsha Khazaie; Nichole R Blatner; Mohammad Wasim Khan; Fotini Gounari; Elias Gounaris; Kristen Dennis; Andreas Bonertz; Fu-Nien Tsai; Matthew J Strouch; Eric Cheon; Joseph D Phillips; Philipp Beckhove; David J Bentrem
Journal:  Cancer Metastasis Rev       Date:  2011-03       Impact factor: 9.264

3.  Active-specific immunotherapy for non-small cell lung cancer.

Authors:  Hauke Winter; Natasja K van den Engel; Margareta Rusan; Nina Schupp; Christian H Poehlein; Hong-Ming Hu; Rudolf A Hatz; Walter J Urba; Karl-Walter Jauch; Bernard A Fox; Dominik Rüttinger
Journal:  J Thorac Dis       Date:  2011-06       Impact factor: 2.895

4.  Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

Authors:  Charles Butts; Nevin Murray; Andrew Maksymiuk; Glenwood Goss; Ernie Marshall; Denis Soulières; Yvon Cormier; Peter Ellis; Allan Price; Ravinder Sawhney; Mary Davis; Janine Mansi; Colum Smith; Dimitrios Vergidis; Paul Ellis; Mary MacNeil; Martin Palmer
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

5.  Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.

Authors:  John Nemunaitis; Robert O Dillman; Paul O Schwarzenberger; Neil Senzer; Casey Cunningham; Jodi Cutler; Alex Tong; Padmasini Kumar; Beena Pappen; Cody Hamilton; Edward DeVol; Phillip B Maples; Lily Liu; Terry Chamberlin; Daniel L Shawler; Habib Fakhrai
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

6.  TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.

Authors:  Zhan Yao; Silvia Fenoglio; Ding Cheng Gao; Matthew Camiolo; Brendon Stiles; Trine Lindsted; Michaela Schlederer; Chris Johns; Nasser Altorki; Vivek Mittal; Lukas Kenner; Raffaella Sordella
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

7.  Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses.

Authors:  Gonzalo de la Rosa; De Yang; Poonam Tewary; Atul Varadhachary; Joost J Oppenheim
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

8.  Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.

Authors:  W M Liu; D W Fowler; P Smith; A G Dalgleish
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

9.  Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors.

Authors:  Michela Spadaro; Claudia Curcio; Atul Varadhachary; Federica Cavallo; Jose Engelmayer; Paul Blezinger; Federica Pericle; Guido Forni
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results.

Authors:  M E R O'Brien; H Anderson; E Kaukel; K O'Byrne; M Pawlicki; J Von Pawel; M Reck
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.